NONMEM Users Network Archive

Hosted by Cognigen

UMB is accepting applications for its 100% Online MS in Pharmacometrics program 2016!

From: Gopalakrishnan, Mathangi <mgopalakrishnan>
Date: Tue, 26 Jan 2016 20:48:36 +0000

The objective of the MS in Pharmacometrics program is to allow current prof=
essionals to acquire skills and knowledge to plan, perform, and interpret p=
harmacometric analyses with the goal of influencing key drug development, r=
egulatory, and therapeutic decisions. The program offers theoretical and ap=
plied technical knowledge together with necessary business skills tailored =
for the pharmaceutical sector. All courses will follow case-based study and=
 are 100% online.

Here is a student testimonial:

"Upon entering the Pharmacometrics program, the singular goal is made clear=
 to train leaders capable of influencing decisions. The program immediately=
 engages you in the practice of the Decisions/Information/Analysis methodol=
ogy via an orchestrated series of live sessions, recorded lectures, discuss=
ions with fellow students and faculty, practice problems, and individual an=
d group case study projects- all conveniently accessed over the internet. A=
ppropriately positioning pharmacometric analyses as a tool and creating a s=
trong focus on systematic decision-making is what will allow the practition=
ers of pharmacometrics to drive drug development and regulatory successes. =
 Although still early in the program, I sense that we've laid a solid found=
ation, and look forward to further implementing the process."

- Carl LeCerte, Senior Investigator, Quantitative Pharmacology

For more details and information on courses offered and how to apply please=
 follow the link:

Additional inquiries may be sent to execms>


Mathangi Gopalakrishnan
Research Assistant Professor
Ph: 410-706-7842
Email: mgopalakrishnan

(image/png attachment: image002.png)

Received on Tue Jan 26 2016 - 15:48:36 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: